Two Sigma Investments, LP Beyond Spring Inc. Transaction History

Two Sigma Investments, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.75 - $1.16 $11,148 - $17,243	-14,865 Reduced 42.92%	19,773 $15,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.39 $15,854 - $24,761	-17,814 Reduced 33.96%	34,638 $40,000
Q1 2023 May 15, 2023	BUY	$1.06 - $3.05 $55,599 - $159,978	52,452 New	52,452 $58,000
Q3 2022 Nov 14, 2022	SELL	$0.97 - $1.81 $57,204 - $106,742	-58,974 Reduced 66.38%	29,863 $30,000
Q2 2022 Aug 15, 2022	SELL	$1.13 - $2.66 $238,602 - $561,666	-211,153 Reduced 70.39%	88,837 $128,000
Q1 2022 May 16, 2022	SELL	$1.68 - $5.01 $287,135 - $856,279	-170,914 Reduced 36.29%	299,990 $660,000
Q4 2021 Feb 14, 2022	BUY	$4.02 - $16.84 $572,841 - $2.4 Million	142,498 Added 43.39%	470,904 $2.13 Million
Q3 2021 Nov 15, 2021	BUY	$9.26 - $31.31 $3.04 Million - $10.3 Million	328,406 New	328,406 $5.18 Million
Q2 2021 Aug 16, 2021	SELL	$9.37 - $12.12 $517,383 - $669,230	-55,217 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$10.61 - $15.77 $585,852 - $870,772	55,217 New	55,217 $611,000

5.55M

26K

2.4K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $66.6M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.